Joel Credle

Biography
Joel J. Credle, Ph.D., is a co-founder of Infinity Bio and serves as its Director of Research and Development. With over 15 years of molecular biology experience, he specializes in developing high-plex next-generation assays at Infinity Bio. His innovations include MIPSA, a molecular display technology, which creates synthetic DNA-barcoded antigen peptide andor ORFeome-scale libraries of full-length proteins to deeply characterize antibody reactivies. At Infinity Bio, he leads RD efforts to develop new MIPSA libraries including HuSIGHT, which covers the entire human proteome with full-length proteins and peptides for most comprehensive detection of autoantibodies. Dr. Credle earned his Ph.D. from Georgetown University and completed postdoctoral training with Dr. H. Benjamin Larman in the Laboratory for Precision Immunology at Johns Hopkins University School of Medicine.

---

Talk
Measuring the Circulating Antibody Reactome for Translational Biomarker Research
Infinity Bio is the antibody reactome profiling company. Our technology translates the antibody reactome, the set of all possible antibody-antigen binding interactions. We add a crucial dimension to multiomics studies by detecting antibodies targeting all known human-infecting viruses, and self-proteins, thus enabling the identification of novel biomarkers and disease mechanism.

Spatial Showcase:
Infinity Bio
Infinity Bio leverages an antigen display technology for antibody reactome profiling and comprehensively measures the repertoire of reactivities against the entire human proteome or virome. Identifying pre-existing or de-novo (auto) antibody reactivities could reveal novel biomarkers of disease and clinical outcomes.